Detailed Narrative
Strong Financial Performance in Q4 and FY25
SMS Pharmaceuticals reported a robust Q4 FY25, with revenue growing 43% year-on-year to INR248 crores and gross profit increasing 18% to INR75 crores. For the full fiscal year 2025, revenue rose 10% to INR783 crores, and PAT saw a significant 39% year-on-year growth, reaching INR69 crores. This performance was attributed to volume growth, cost efficiencies, and a focus on execution, leading to a 330 basis point improvement in full-year gross margins to 33%.
Strategic Backward Integration and Margin Expansion
The company has successfully completed all necessary licenses and approvals for its backward integration project, with commercial production of key intermediates slated to begin in Q2 FY26. This initiative is expected to materially improve margins, building on the 30% contribution from backward integration to gross margin in Q4 FY25. The primary focus for backward integration is on high-volume commodity products, such as anti-diabetic and anti-epileptic segments, to mitigate cost pressure and enhance profitability.
Significant Capex for Capacity Expansion and New Products
SMS Pharma invested INR150 crores in FY25, primarily for backward integration projects. Looking ahead, a new capex plan of INR250 crores is approved for the next 18 months, aimed at expanding capacity for existing and new products, as well as growing the CMO business. The company targets an asset turnover of 1 for this new capex, with commercials expected to commence in early FY27, indicating a strategic push for efficient capital deployment and future revenue generation.
Aggressive Growth Targets for FY26
For FY26, SMS Pharma is targeting a 20% revenue growth and aiming to expand its EBITDA margins to 20%. This optimistic outlook is underpinned by the benefits of backward integration, improved scale, and volume growth across key products. Specifically, the company plans to significantly increase ibuprofen production, targeting 5,000 tons in FY26, up from 2,200 MT in FY25, and aims to grow its regulated market share for ibuprofen to 70%.
Inventory Management and Product Mix Strategy
The company is currently holding INR285 crores in inventory, which includes INR40 crores of slow-moving older products like HCQ. While acknowledging plans to reduce overall inventory levels in FY26, management explained that higher inventory is necessary for high-volume commodity products like ibuprofen, tenofovir, and sitagliptin due to short lead times (4-5 days). The strategy emphasizes a diversified product mix to navigate market volatility🌐 and maintain margin stability.
Segmental Performance and Market Penetration
In FY25, the anti-inflammatory segment grew 22% to INR148 crores, and ARV products increased 15% to INR163 crores. The anti-epileptic segment showed the fastest growth at 106% to INR29 crores, while anti-diabetic, the largest segment, grew 5% to INR185 crores despite price softening. The company is actively deepening its customer base in regulated markets and has onboarded several large clients, improving revenue visibility and customer stickiness.